Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116662 · ClinicalTrials.gov registry record · Phase 2
An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
A Phase 2 study, sponsored by Graceway Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 84
- Enrollment target
NCT00116662 is a Phase 2 study that has completed, run by Graceway Pharmaceuticals. The registered enrollment target is 84 participants.
The verdict
NCT00116662, a Phase 2 study, has completed, sponsored by Graceway Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 84 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks. A second purpose is to evaluate the safety of the drug.
Interventions
- DRUG Resiquimod
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2005-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00116662
The ClinicalTrials.gov registry entry for NCT00116662 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Graceway Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Resiquimod is the first listed.
NCT00116662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00116662 about?
NCT00116662 is a clinical study titled "An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects". The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for up to twelve weeks. A second purpose is to evaluate the safety of the drug.
What is the current status of trial NCT00116662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 84 participants. The study started on 2005-03.
What interventions are being tested in trial NCT00116662?
The interventions under investigation include: Resiquimod (DRUG).
Who is sponsoring clinical trial NCT00116662?
This trial is sponsored by Graceway Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.